Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Acute Blood Purification

Editor(s): Suzuki H. (Saitama) 
Hirasawa H. (Chiba) 
Cover

Non-renal Indication

Treatment of Severe Sepsis and Septic Shock by CHDF Using a PMMA Membrane Hemofilter as a Cytokine Modulator

Nakamura M. · Oda S. · Sadahiro T. · Hirayama Y. · Watanabe E. · Tateishi Y. · Nakada T. · Hirasawa H.

Author affiliations

Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba, Japan

Related Articles for ""

Suzuki H, Hirasawa H (eds): Acute Blood Purification. Contrib Nephrol. Basel, Karger, 2010, vol 166, pp 73–82

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Non-renal Indication

Published online: May 07, 2010
Cover Date: 2010

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9478-3 (Print)
eISBN: 978-3-8055-9479-0 (Online)

Abstract

It has been reported that various types of blood purification intended for the removal of humoral mediators, such as cytokines, were performed in patients with severe sepsis/septic shock. While high-volume hemofiltration, hemofiltration using high cut-off membrane filters, and direct hemoperfusion with a polymyxin-B immobilized column are widely used in the treatment of severe sepsis/septic shock, we perform continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF), which shows an excellent cytokine-adsorbing capacity, for the treatment of severe sepsis/septic shock. In our previous study, it was found that PMMA-CHDF could efficiently remove various pro-inflammatory cytokines such as TNFΑ, IL-6 and IL-8 from the bloodstream, resulting in early recovery from septic shock. Furthermore, PMMA-CHDF could remove anti-inflammatory cytokines such as IL-10 from bloodstream, suggesting that it might improve immunoparalysis as well. These findings suggest that PMMA-CHDF is useful for the treatment of patients with severe sepsis/septic shock as a cytokine modulator.

© 2010 S. Karger AG, Basel


References

  1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
  2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150
  3. Volk HD, Reinke P, Dö cke WD: Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 2000;74:162-177
  4. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R: Interpreting the mechanism of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801
  5. Webster NR, Galley HF: Immunomodulation in the critically ill. Br J Anaesth 2009;103:70-81
  6. Cinel I, Opal SM: Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009;37:291-304
  7. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-853
  8. Sieberth HG, Kierdorf HP: Is cytokine removal by continuous hemofiltration feasible?. Kidney Int Suppl 1999;72:S79-S83
  9. Honore PM, Joannes-Boyau O, Boer W, Collin V: High-volume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009;28:1-11
  10. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N: High cut-off point membranes in septic acute renal failure: systematic review. Int J Artif Organs 2007;30:1031-1041
  11. Matsuda K, Hirasawa H, Oda S, Shiga H, Nakanishi K: Current topics on cytokine removal technologies. Ther Apher 2001;5:306-314
  12. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M: Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 2002;6:193-198
  13. Hirasawa H, Oda S, Matsuda K: Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 2007;156:365-370
  14. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M: Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005;29:169-175
  15. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R, Hirasawa H: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-263
  16. Shimizu T, Endo Y, Tsuchihashi H, Akabori H, Yamamoto H, Tani T: Endotoxin apheresis for sepsis. Transfus Apher Sci 2006;35:271-282
  17. Hirasawa H, Oda S, Shiga H, Matsuda K, Nakanishi K: Endotoxin adsorption or hemodiafiltration in the treatment of multiple organ failure. Curr Opin Crit Care 2000;6:421-425
  18. Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-3587
  19. Piccinni P, Dan M, Carraro R, Carraro R, Lieta E, Marafon S, Zamperetti N, Brendolan A, D'Intini V, Tetta C, Bellomo R, Ronco C: Early isovolemic haemofiltration in oligouric patients with septic shock. Intensive Care Med 2006;32:80-86
  20. Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J, Castillo L, Andresen M, Dougnac A, Bugedo G, Hernandez G: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713-722
  21. Bousskey N, Chiche A, Faure K, Devos P, Guery B, d'Escrivan T, Georges H, Leroy O: A pilot study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008;34:1646-1653
  22. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-405
  23. Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S: Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006;10:12-18
  24. Nakamura T, Sugaya T, Koide H: Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion. Shock 2009;31:454-459
  25. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-2452
  26. Hirano T, Hirasawa H, Oda S, Shiga H, Nakanishi K, Matsuda K, Nakamura M, Asai T, Kitamura N: Modulation of polymorpho-nuclear leukocyte apoptosis in the critically ill by removal of cytokines with continuous hemodiafiltration. Blood Purif 2004;22:188-197
  27. Schefold JC, Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, Volk HD, Reinke P: A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5A. Shock 2007;28:418-425
  28. Schefold JC, Hasper D, Jorres A: Organ crosstalk in critically ill patients: hemofiltration and immunomodulation in sepsis. Blood Purif 2009;28:116-123
  29. Watanabe E, Hirasawa H, Oda S, Matsuda K, Hatano M, Tokuhisa T: Extremely high inter-leukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005;33:89-97
  30. Smith A, Lamagni TL, Oliver I, Efstratiou A, George RC, Stuart JM: Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis?. Lancet Infect Dis 2005;5:494-500

Article / Publication Details

First-Page Preview
Abstract of Non-renal Indication

Published online: May 07, 2010
Cover Date: 2010

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9478-3 (Print)
eISBN: 978-3-8055-9479-0 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.